Tier A — narrow indication only

PT-141 (Bremelanotide)

Melanocortin receptor agonist, primarily MC4R.

Conceptual chain illustration for PT-141 (Bremelanotide) — for representation purposes only. Not the compound's verified molecular structure.

Evidence

FDA approved (marketed as Vyleesi) for hypoactive sexual desire disorder in premenopausal women. Real trial data exists for that specific indication only.

This page is intentionally brief. Sexual-dysfunction-related conditions sit under scheduled advertising restrictions in several jurisdictions, India included. We're not expanding on indication-specific claims here.

Known effects

Nausea and flushing are commonly reported in trial data.

Have a question?